Zobrazeno 1 - 10
of 73
pro vyhledávání: '"H. Esperou-Bourdeau"'
Autor:
Agnès Devergie, L. Sedel, H. Esperou Bourdeau, Patricia Ribaud, Gérard Socié, Eliane Gluckman, F. Selimi, Jacques Frija
Publikováno v:
British Journal of Haematology. 86:624-628
In the present study we describe the incidence, clinical course, and management of avascular necrosis of bone following allogeneic bone marrow transplantation, and identify risk factors related to its development. All patients developing avascular ne
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71f6573f7ae6e96c530e9ab1a92cd3af
https://doi.org/10.1111/j.1365-2141.1994.tb04795.x
https://doi.org/10.1111/j.1365-2141.1994.tb04795.x
Autor:
Brigitte Raynal, Olivier Brison, G. Socie, Agnès Devergie, J. Landman, Eliane Gluckman, H. Esperou-Bourdeau
Publikováno v:
British Journal of Haematology. 80:391-398
Summary. Chimaerism was studied early (2 weeks to 3 months) during haematopoietic reconstitution after bone marrow transplantation in 18 severe aplastic anaemia patients (acquired SAA: 14 patients; Fanconi anaemia: four patients). Fourteen patients r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e73a82c37741985d7493dfac8da476b
https://doi.org/10.1111/j.1365-2141.1992.tb08150.x
https://doi.org/10.1111/j.1365-2141.1992.tb08150.x
Autor:
H. Esperou-Bourdeau, A. Devergie, E. Gluckman, A. Bussel, Lehn P, A. Quessar, I. Jolivet, M.C. Mazeron, R. Traineau
Publikováno v:
Revue Française de Transfusion et d'Hémobiologie. 34:395-402
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60ff0ddcd7c74559a4eceafd41fd17aa
https://doi.org/10.1016/s1140-4639(05)80215-1
https://doi.org/10.1016/s1140-4639(05)80215-1
Autor:
M Cavazzana-Cavo, François Demeocq, Francois Dreyfus, Noel-Jean Milpied, Agnès Buzyn, M Kuentz, Denis Caillot, Xavier Thomas, G Souillet, B Delmas-Marsalet, Anne Thiebaut, Bruno Lioure, M. Attal, P. Y. Leprise, Michel Leporrier, J. Y. Cahn, A Sadoun, A Belhabri, Laurent Sutton, J. H. Bourhis, Marie-Cécile Michallet, Norbert Ifrah, Pierre Bordigoni, André Baruchel, Jean-Jacques Sotto, J P Jouet, F. Bernaudin, Denis Guyotat, J P Vannier, J P Vernant, N. Gratecos, Bernard Rio, Nathalie Fegueux, H. Esperou-Bourdeau, Josy Reiffers, Gérard Socié, H. Tilly, M L Tanguy, T de Revel, Eric Archimbaud, Didier Blaise, G. Michel
Publikováno v:
Bone marrow transplantation. 26(11)
To assess the place of allogeneic hematopoietic stem cell transplantation (HSCT) in the advanced stage of acute myeloid leukemia (AML), we retrospectively analyzed 379 consecutive patients who underwent allogeneic HSCT for advanced AML. The median fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db1dd81761f1b63bd7baf6f647ea939c
https://pubmed.ncbi.nlm.nih.gov/11149725
https://pubmed.ncbi.nlm.nih.gov/11149725
Autor:
Gérard Couillaud, G. Michel, Guy Leverger, Brigitte Nelken, M. D. Tabone, J. P. Dommergues, J P Vannier, Pierre Bordigoni, Jean-Pierre Lamagnere, Anne Auvrignon, André Baruchel, Thierry Leblanc, Christophe Bergeron, Isabelle Thuret, L. de Lumley, G. Schaison, H. Esperou-Bourdeau, Y Perel
Publikováno v:
Hematology and cell therapy. 38(2)
In the LAME89/91 protocol, children with acute myeloid leukemia (AML) who achieved complete remission (CR) after induction chemotherapy, were treated either with allogeneic bone marrow transplantation (BMT) if they had an HLA-compatible related donor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5226743eae4fcb4c166b0e2992b43aee
https://pubmed.ncbi.nlm.nih.gov/8931998
https://pubmed.ncbi.nlm.nih.gov/8931998
Autor:
A, von Bueltzingsloewen, H, Esperou-Bourdeau, G, Souillet, F, Demeocq, F, Mechinaud-Lacroix, G, Michel, A, Sadoun, F, Bernaudin, G, Cornu, J, Donadieu
Publikováno v:
Bone marrow transplantation. 16(4)
A subgroup of children with ALL remains at high risk of relapse despite the administration of intensive chemotherapeutic protocols and may benefit from allogeneic BMT. The cytoreductive regimen used most often combines TBI with cyclophosphamide. Neve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a788a3646266f5d5c6729bd653c0af40
https://pubmed.ncbi.nlm.nih.gov/8528167
https://pubmed.ncbi.nlm.nih.gov/8528167
Autor:
H, Esperou-Bourdeau
Publikováno v:
La Revue du praticien. 44(14)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5ba18696aff2c4dfb37f507e62d0eac6
https://pubmed.ncbi.nlm.nih.gov/7939273
https://pubmed.ncbi.nlm.nih.gov/7939273
Publikováno v:
Pathologie-biologie. 42(7)
Invasive aspergillosis is the most frequent cause of infectious death after allogeneic bone marrow transplantation. Risk factors include the patient's condition (granulocytopenia, immunosuppression) and his environment (air spores count). Pulmonary i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b1d2e8db9fa1b3fb2762ec821c58781d
https://pubmed.ncbi.nlm.nih.gov/7877857
https://pubmed.ncbi.nlm.nih.gov/7877857
Autor:
G, Socié, M, Henry-Amar, A, Devergie, H, Esperou-Bourdeau, P, Ribaud, R, Traineau, E, Gluckman
Publikováno v:
Nouvelle revue francaise d'hematologie. 36
Among late effects occurring after allogeneic bone marrow transplantation malignant diseases are of particular clinical concern as more patients survive the early phase after transplantation and remain free of their original disease. In this paper we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e53c58863ac17e66619ba70c2cbf16ab
https://pubmed.ncbi.nlm.nih.gov/8177721
https://pubmed.ncbi.nlm.nih.gov/8177721
Progress in the prevention of cytomegalovirus infection after allogeneic bone marrow transplantation
Autor:
A, Devergie, R, Traineau, H, Esperou-Bourdeau, P, Ribaud, G, Socié, P, Richard, F, Selimi, I, Hirsch, E, Gluckman
Publikováno v:
Nouvelle revue francaise d'hematologie. 36
There has been substantial progress in preventing and treating CMV infection. Prophylaxis with CMV screened blood products, IVIG and antiviral drugs (high dose acyclovir and/or Ganciclovir) considerably reduce the incidence of CMV disease and nearly
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::955535e5c67298d7a3300c33dea37968
https://pubmed.ncbi.nlm.nih.gov/8177726
https://pubmed.ncbi.nlm.nih.gov/8177726